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This study is an analysis of the criteria considered when prescribing concomitant chemotherapy and radiotherapy, as a routine
treatment for patients with anal canal cancer, and related complications. Between 1990 and 1996, 67 patients were treated at Institut
Curie for invasive, nonmetastatic cancer of the anal canal. Median age was 65 years (range, 35–90 years). TNM stage distribution was
as follows: seven T1, 17 T2, 27 T3, 16 T4, and 22 Nþ patients. A total of 29 patients (i.e., five T1/T2, and 24 T3/T4) received
concurrent chemotherapy and radiotherapy. Radiotherapy volumes and dose and prescribed dose for chemotherapy were not
statistically different from one group of patients to another. Only 55% of T3/T4 patients underwent standard chemoradiation
treatment for anal canal cancer. Age was the one of main factor in determining if the patient would undergo concomitant
chemotherapy or not. For the T3/T4 patients, concomitant chemotherapy was prescribed to 69% of patients o55 years, 90% of
patients between 56 and 64 years, 45% of patients between 65 and 75 years, and 20% of patients over 75 years (Po0.02).Overall
survival at 4 years was 66%. The 4 years overall survival rate of T3/T4 patients, who underwent concomitant chemotherapy, was 72%,
and that of T3/T4 patient who did not, was 34% (Po0.04). The patients who did not undergo chemotherapy were significantly older.
The difference in cause-specific survival rates (72 vs 48%) was not significant. Relapse-free interval without local recurrence at 4 years
was 70%. Relapse-free interval of T3/T4 patients was 78% with chemotherapy and 60% without chemotherapy (p¼NS). Rates of
treatment discontinuation and early toxicity were not statistically different. Late complications occurred in 33 patients, eight of whom
had grade 2/3 tumours. At 2 years, complications occurred in 39% of patients who had undergone concomitant chemotherapy, and
in 20% of patients who had not (po0.02). Differences in grade 2/3 complications were not significant. In conclusion, although
radiotherapy with concomitant chemotherapy is considered the current ‘gold-standard’ treatment for anal canal cancer, in our daily
experience, only 55% of our T3/T4 patients have undergone this treatment. The remainder did not undergo chemotherapy mainly
because they were deemed too old. In this series, no increase in local control and cause-specific survival was observed in patients
who received concomitant chemotherapy; this may be due to the small number of patients included in the series. The increased rate
of late complications observed in patients who received the combined treatment, however, provides evidence that this treatment
should be restricted to younger patients without comorbidity and therefore justifies our position. Perhaps reduction of doses of
chemotherapy must be discussed for older patients.
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Carcinoma of the anal canal is a relatively uncommon tumour
(1–3% of all cancers of the lower digestive tract) (Beahrs, 1985).
The standard treatment for anal cancer is concurrent chemother-
apy and radiotherapy. Two publications, reporting on randomised
trials of concurrent chemotherapy and radiotherapy, showed the
advantages of this association over radiotherapy alone, in terms of
local control and colostomy-free (UKCCCR, 1996; Bartelink et al,
1997). In these papers, however, the combined treatment was
mainly reserved for T3/T4 or Nþ patients.
In our experience, patients with T3/T4 and Nþ disease are not
so frequent. For instance, in a series of 346 patients treated for anal
canal cancer at our institution between 1967 and 1996, 33% had a
T3/T4 tumour and 23% had an Nþ tumour (Chauveinc et al,
2003). If concurrent chemotherapy and radiotherapy is the ‘gold
standard’ of treatment for large tumours, this treatment was no
validated for the smaller-sized tumours.
In this study, we analysed the criteria considered when
determining which treatment should be prescribed (concurrent
chemotherapy and radiotherapy or radiotherapy alone), the
associated results, and complications. This study conducted at
Institut Curie includes 67 patients treated for anal canal cancer
with 5FU/cisplatin concurrent chemotherapy and radiotherapy,
between 1990 and 1996.
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The sample consists of 67 patients with locally advanced
nonmetastatic anal canal cancer who were treated at our
institution between 1990 and 1996. The sample excluded patients
with tumours of the anal margin, adenocarcinomas, and melano-
mas. Pretreatment evaluation included history, physical examina-
tion, chest radiography, tumour biopsies, standard laboratory
tests, and ultrasound (US) or CT-based evaluation of the liver and
lymph nodes. Endorectal ultrasound was performed on a small
number of patients (the most recent cases only), therefore the
results of this test will not be considered in this study. The median
duration of follow-up was 48 (10–101) months.
Tumour characteristics and treatments are summarised in
Table 1. The Rousseau staging system was used (Table 2)
(Rousseau et al, 1973). The mean age was 65 years, and the sex
ratio was nine women to one men.
Treatments
Most patients underwent pelvic irradiation. A 4-field box
technique was used. The top field was located at the L5–S1
interspace and the bottom field, 2cm below the lowest margin of
the tumour. The inguinal nodes were only covered by the anterior
field. A complementary electron boost was delivered to the
inguinal nodes.
The prescribed dose at the ICRU point was 50Gy for the pelvis
and 45Gy for N0 nodes. Doses were delivered in five fractions per
week, and fraction doses ranged from 1.8 to 2Gy.
Evaluation was repeated 1 to 2 months following treatment. A
boost of 15–20Gy was delivered to responding patients using
either direct perineal field, reduced 4-field, or brachytherapy.
Based on clinical evaluation results, an additional 20Gy was also
delivered to all nodes involved.
The low-dose rate procedure (with 192-iridium) was used for
patients who underwent brachytherapy. The prescribed dose was
applied to the 85% isodose. When combined with external beam
radiotherapy, the sum of the 85% reference isodose and external
dose was used. Median doses of 48 and 63Gy were delivered to the
pelvis and to the anal canal, respectively (36–75).
Abdominoperineal (AP) resection was performed in patients
who did not respond to a 50Gy treatment, when residual tumour
was detected after completion of the treatment, or in case of local
recurrence. Colostomy alone was performed in patients with
rectovaginal fistulae or severe radiation-induced complications.
Chemotherapy, consisting of a continuous infusion of 5-FU
(600mgm
 2) and cisplatin (20mgm
 2) for 5 days of every 21-day
cycle (J1¼J21), was concomitant with radiotherapy. A total of two
to three courses were given. The treatment is decided at our weekly
meeting with participation of surgeons, radiation, and medical
oncologists as a function of our protocols and patient’s
performance status, tumour and lymph node stage. Usually, we
use concurrent chemotherapy and radiotherapy for T3/T4 or/and
Nþ patients.
Early complications
Early complications were graded according to the NCI common
toxicity criteria, version 2.
Late complications
Late complications were graded according to the Rousseau
classification system (Rousseau et al, 1979) (Table 3). Each
patient’s case was analysed and discussed among two of the
authors (LC and XB).
Statistical analysis
Patients were compared in the two treatment groups with the K
2
test, with Fisher’s exact test when necessary. For continuous
variables, comparison was assessed by the Mann–Whitney test.
Survival, relapse-free interval and late complication rates were
estimated by the Kaplan–Meier method, and compared by the log-
rank test. Curves were calculated from the date of the histological
Table 1 Patient characteristics
Total Chemotherapy Without chemotherapy P
Number of patients 67 29 38
Mean age (years) 65 60.7 67.9 o0.01
Age (years)
p65 35 19 16
66–75 23 8 15 o0.03
475 12 2 10
Pelvic irradiation 1 0 1 NS
Pelvic surgery
11 2 9 NS NS
Stage T1/T2 24 5 19 o0.006
Stage T3/T4 43 24 19
N+ (total) 22 13 9
Inguinal 9 7 2 o0.04
Pelvic 16 9 7 NS
Squamous differentiated 49 17 32 ¼0.064
Squamous undifferentiated 15 10 5 NS
Transitional 3 2 1
Circumference NS
p1/2 49/66 19 30
41/2 17 9 8
Mean high T (cm) 4.4/65 5.34 3.63 o0.001
Tumour size /65 o0.05
p43 4 8 2 6
443 1 2 1 1 0
Dose, anal canal (Gy) 62.6 62.2 NS
Brachytherapy 13 4 9 NS
NS¼nonsignificant. P¼P-value.
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T4 patients in order to restrict patients’ heterogeneity in the two
treatment groups.
RESULTS
Factors considered in the choice of treatment
Results are summarized in Table 1. A total of 29 patients (43.3%)
were treated with radiotherapy and concomitant chemotherapy.
Tumour size, patient’s age, and inguinal nodal status were
considered in selecting treatment.
Concomitant chemotherapy was mostly (Po0.006) delivered to
patients with higher-grade tumours, that is, 55.8% of patients with
a T3/T4 tumour and 67% of patients with a tumour 44cm in size.
A majority of younger patients were treated with concomitant
chemotherapy (Po0.03): 47% of patients under 56 years, 61% of
patients between 56 and 65 years, 34% of patients between 66 and
75 years, and 16% patients over 75 years. For the T3/T4 patients
alone (Figure 1), these rates were 69, 90, 45, and 20%, respectively.
As regards the N status, 59% of Nþ patients underwent
concomitant chemotherapy and 77% for the inguinal Nþ.
Survival
The overall 4-year survival rate was 66%. The 4-year survival rate
of T3/T4 patients (Figure 2) was 72 and 34%, with or without
chemotherapy, respectively (Po0.04). There was, however, no
significant difference in cause-specific survival at 2 years (86 vs
81%) and at 4 years (72 vs 47%).
Relapse-free survival
The overall 4-year relapse-free survival (RFS) was 70%. The 4-year
RFS rates of T3/T4 patients, with or without concomitant
chemotherapy, were 78 and 60%, respectively (NS) (Figure 3).
Early toxicity
Increased incidence of haematological complications was observed
with concurrent chemotherapy (Po0.001 with a w
2 test for the
three ligneous). No difference in the rates of cutaneous, digestive,
and renal complications was noted between both the treatments.
Late complications
Late complications were staged according to our own classification
system (Table 3). In all, 33 patients had late complications for 39
complications – 32 patients had grade 1 complications and seven
patients had grade 2/3 complications. The 2-year complication-free
interval rates without or with chemotherapy were 71.5 and 54% for
all the population, and 73 and 49% for the T3/T4 patients,
respectively. At 4 years, the complication-free interval rates were
64 and 35%, 54 and 32.5%, respectively. The difference was
significant for the T3/T4 (Figure 4).
DISCUSSION
As of late, concurrent chemotherapy and radiotherapy has been
considered the ‘gold-standard’ of treatment for anal canal cancer.
Table 2 TNM classification system by Rousseau
T1 Tumour p1/3 of the circumference of the anal canal, without sphincter
infiltration
T2 Tumour p1/3 of the circumference of the anal canal, with sphincter
infiltration
T3
T3a Tumour with invasion of the rectum p4cm
T3b Tumour with invasion of the rectum 44cm
T4 Extension to others tissues
T4a Vagina or vulva
T4b Other tissues
N0 No lymph node involved
N1 Unilateral inguinal lymph nodes involved
N2 Bilateral inguinal lymph nodes involved
N3 Fixed inguinal lymph nodes involved
Table 3 Complication grading system used
Grade I Minor complications without treatment
Grade II Serious complications requiring medical treatment
Grade III Serious complications requiring surgery
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Figure 1 Delivery of concurrent chemotherapy and radiotherapy
according to age group, in patients with T3/T4 tumours. x: age groups. y:
proportion of patients who underwent concomitant chemotherapy and
radiation therapy (%).
x: time (months)
y: survival rate (%)
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Figure 2 Overall survival for the T3/T4 patients. x: time (months). y:
survival rate (%).
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lAfter a lot of series with different chemotherapies, 5FU and
Mitomycine C (Sischy, 1985; Cummings et al, 1991), 5FU and
Cisplatine (Rich et al, 1993; Doci et al, 1996), Bleomycine (Friberg
et al, 1998), two articles reporting on randomised trials showed the
advantages of the 5FU/Mitomycine C combination treatment in
terms of local control and colostomy-free interval (UKCCCR, 1996;
Bartelink et al, 1997). In the first series, however, this treatment
was only delivered to T3/T4 and Nþ patients. In the second study
(UKCCCR, 1996), although all patients received radiotherapy and
concomitant chemotherapy, the patient distribution showed that
more than 53% of patients had a T3/T4 tumour, and close to 20%
of patients had an Nþ tumour. Moreover, for both series the
combined treatment was restricted to younger patients.
In a previous study (Chauveinc et al, 2003), the majority of our
patients had a UICC T1/T2 (International-Union-Against-Cancer,
1987) tumour (65%) and were over 65 years old (55%). If
chemotherapy is not indicated for older patients and patients with
small tumours, what would be our routine prescription for these
patients?
In order to answer this question, we analysed results obtained
with 67 anal canal cancer patients treated with either radiotherapy
alone, or 5FU/cisplatin concurrent chemotherapy and radiation, at
our institution between 1990 and 1996.
In this series, only 29 patients (43.3%) were given the combined
treatment. Factors considered to determine the indication for this
treatment included tumour size and T stage. The combined
treatment was mostly given to patients with large-sized tumours,
that is, 55.8% of T3/T4 patients and 67% of patients with a tumour
X4cm in size. All of these patients should have normally had
chemotherapy alone. Why were not the remainder given che-
motherapy?
The main reason was their age. A larger proportion of younger
patients had concurrent chemotherapy and radiation (Po0.03):
nearly 50% of patients p65 years vs nearly 20% of patients were
over 75 years. In T3/T4 patient population, the rates were 69% of
patients under 55 years, 90% of patients between 56 and 65 years,
45% of patients between 66 and 75 years, and 20% of patients over
75 years.
We naturally did not prescribe chemotherapy for the older
patients, even when tumour size would have warranted che-
motherapy. Early local complication rate did not seem to increase
with concomitant chemotherapy; only the haematological toxicity
increased. Results obtained regarding late toxicity greatly influ-
enced our choice of treatment. We analysed late complications
with our own very simple and reproducible classification system.
The number of complications significantly increased after
concomitant chemotherapy. Patients experienced mostly minor,
but nonetheless disturbing, complications such as diarrhoea
(principally), rectum haemorrhage, and anal fibrosis. Complica-
tions required medical treatment in eight patients; however, none
of the patients had to undergo surgery.
The authors of the two aforementioned studies apparently
obtained different results (UKCCCR, 1996; Bartelink et al, 1997);
they failed to mention differences in complication rates. Some
differences, however, could be noted. Indeed, in the first series
(Bartelink et al, 1997) early complication rates, especially those
pertaining to haematological complications, were higher in
patients who had undergone concomitant chemotherapy. We do
not know which classification system was used to grade
complications, but it was obviously different from ours. In the
second series (UKCCCR, 1996), only serious complications were
analysed; in our series, we also considered grade 1 toxicity.
And the most important point is the difference of the
chemotherapy used. In our series, the treatment was a 5FU/
cisplatin combination, more frequently using in France for anal
cancer (Gerard et al, 1998) and cervix cancer (Nguyen et al, 2002).
If the early toxicity with this treatment was low, with no related
death, the cisplatin could modify the late toxicity.
In another retrospective study, authors showed an increased
complication rate after concurrent chemotherapy and radio-
therapy (Flam et al, 1987). All of the severe complications were
experienced by elderly patients who had undergone the combined
treatment (Allal et al, 1997, ). These results reflect our findings.
In conclusion, our decision not to treat older patients with
comorbidity with concurrent chemotherapy and radiotherapy
is supported by the fact that an increased late complications
rate is associated to this combined treatment. Perhaps reduction
of doses of chemotherapy must be discussed for this population of
patients.
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Figure 3 Relapse-free survival for T3/T4 patients. x: time (months). y:
DFS rate (%).
y: proportion of patients who experienced complications following
    treatment (%)
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Figure 4 Complications observed after anal canal cancer treatment by
radiation therapy alone or concurrent chemotherapy and radiation therapy.
y: proportion of patients who experienced complications following
treatment (%). þx: time (months).
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